Paul Terrill

After completing his PhD in statistics Paul started his career working as a statistician in the agrochemical industry at Jealott’s Hill, Berkshire before becoming a statistical trainer for SAS. He moved into the pharmaceutical industry in 2005 and primarily provides support to biotech and small pharmaceutical companies who lack in-house statistical expertise. Paul has been on the PSI Scientific Committee since 2014 and became the Scientific Committee Chair and a PSI Board Member in October 2017. In 2020 Paul took on the role of the Chair for the annual PSI conference. Outside of work Paul enjoys running and archery.

David Lawrence

Since completing my PhD in epidemiology at the University of Edinburgh, UK, in 1999 I have worked as a clinical trial statistician on oncology and respiratory trials in both academia and the pharmaceutical industry. I currently work for Novartis in Switzerland leading the global statistical team on a large phase III program in asthma..

Rachael Lawrence

Rachael is Director and a Principal Statistician at Adelphi Values Patient Centered outcomes team, focused on the analysis and interpretation of PRO data in clinical trials. Previously Rachael has worked as a freelance consultant statistician and prior to that worked at AstraZeneca for sixteen years, including as a clinical trial statistician on phase III-IV oncology projects. Rachael has been a member of the PSI Scientific Committee since 2016, and a PSI Board Member and chair of Scientific Committee since June 2019. Outside of work she enjoys time with her family (husband and two sons) and loves fell running.

Amitava Mukhopadhyay

Amitava is an Associate Director, BioStatistics at Cytel since 2015. He has more than fifteen years of experience in the pharmaceutical industry with all phases of drug development in different therapeutic areas including oncology and ophthalmology. He was in academia for over a decade. His main focused areas are statistical methods in pharmacovigilance and spatio-temporal disease dynamics for personalized medicine. He has been engaged in PSI Scientific Committee since 2018.

Jennifer Gilbride

Jennifer is a Statistics Leader at GSK in Stevenage, and has been at GSK since 2016. Jennifer has worked in Biometrics for around 25 years. During her career she has worked mainly in late phase and in several therapeutic areas; most recently Lupus, Rheumatoid Arthritis and Pain. Jennifer completed her first degree in Mathematics and Economics at the University of Durham, followed by an MSc in Applied Statistics from Sheffield Hallam University.

Jennifer joined the Scientific Committee in 2014 and has enjoyed working with the team on conferences, one day events and webinars.

Outside of work Jennifer enjoys walking, travel, good food and time with family and friends.

Julia Niewczas

Julia is a clinical trial design methodology expert in the Biopharmaceuticals Statistical Innovation team at AstraZeneca. She consults teams on complex trial designs in Phase 2 and 3. Her areas of expertise include adaptive designs, group sequential designs and multiplicity. Recently, she developed interest in Bayesian designs. She received her BSc and MSc at Lancaster University in the UK and holds a PhD in Biostatistics from Medical University of Vienna.

Julia joined the PSI Scientific Committee in June 2020.

Julia Saperia

Julia is a statistical assessor at the Medicines and Healthcare products Regulatory Agency, where she has been working since 2012. She works across therapeutic areas and enjoys the variety and challenges. She completed her MSc in Statistics with Applications in Medicine from the University of Southampton in 2003 and between then and starting at the MHRA she has worked as a statistician and systematic reviewer in academia and in the public sector. She joined the PSI scientific committee in 2016. In her spare time -- oh, wait, what is that again? -- she sings (quite well) and plays the violin (very badly).

Kristina Weber

Kristina is a Senior Statistical Scientist at Roche, where she works primarily on late phase Neuroscience studies since 2018. She has previously worked as a statistician at the Medical School Hannover, Germany, where she worked on clinical trials across different indications and development phases. Kristina holds a PhD from the Medical School Hannover and holds a BSc and MSc in Mathematics. She has joined the PSI Scientific Committee beginning of 2020.

Maria Efstathiou

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Martin Jenkins

Martin Jenkins is a Biometrics Team Leader at AstraZeneca in Cambridge. He is the statistical lead for several late stage product teams in the respiratory therapy area, and also has experience in rheumatology, dermatology and inflammatory diseases. Martin initially joined AstraZeneca in 2006, providing statistical support to translational science before moving into later phase clinical trials. He has been a member of the PSI scientific committee since 2017 and prior to that chaired the PSI Biomarker Special Interest Group for 6 years. He has published or presented in the fields of adaptive phase II/III seamless designs, biomarkers and estimands. Martin holds a undergraduate degree and masters in Mathematics from Cambridge University.

Rosie Leach

Rosie obtained an undergraduate degree in Mathematics in 2014 and then completed her MSc in Medical Statistics in 2016. Since then, she has worked as a statistician at Numerus UK and IQVIA. Rosie joined the Scientific Committee in October 2018. Outside of work, Rosie enjoys playing the drums.

Russell Jones

Russell is a Director, Biostatistics at Orchard Therapeutics. After an honours degree in Mathematics he spent a few years teaching secondary mathematics with varying outcomes. The result of which led to him undertaking an MSc in Statistics at Southampton in 2006. Since then he has worked in varied areas of Clinical Biostatistics with particular interest in missing data topics. He has been a member of the PSI Scientific Committee since 2011.

Sarah Williams

Sarah is a Senior Statistical Scientist at Roche, where she has worked for the past 17 years. She has previously worked in the following therapeutic areas: inflammation, oncology and currently works in infectious diseases.

Sarah joined the Scientific Committee in October 2017 and is enjoying getting to know the committee members and helping to organise events.

Outside of work Sarah enjoys running, yoga and days out with her family.

Sue Todd

Sue is Professor of Medical Statistics within the Department of Mathematics and Statistics at the University of Reading and has over 25 years’ experience as an applied academic statistician working in the fields of clinical trials and epidemiology. Her particular research areas of interest are adaptive designs and sequential clinical trials. Recent research has considered methodology for novel study design and analysis in these areas, in particular multi-arm multi-stage clinical trials involving treatment selection and multiple endpoints of interest.

Tobias Mütze

Tobias is a statistical methodologist at Novartis in Basel, Switzerland, and works primarily on late phase studies. Previously, Tobias worked as a CMC statistician in the development of vaccines and biologicals. His current research interests are adaptive clinical trial designs, recurrent event modelling, estimands, and more recently missing data methodology. He received his PhD in the area of biostatistics from the University of Göttingen, Germany, and holds a BSc and a MSc in mathematics. Tobias joined the PSI Scientific Committee in January 2019.

Tom Burnett

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Kate Taylor

Kate is a Biostatistics Senior Manager working for Amgen in their Uxbridge office, where she has been for the last 8 years. During that time, she has worked across a number of disease areas and phases in their oncology pipeline. She has also worked in a CRO and completed a placement year at GSK as well as working in market research for a number of years. Kate has been a member of the PSI Scientific Committee since 2016 and was the Conference Chair and a board member for 2019 and 2020. She was also a part of the PSI CALC group for 2 years. Outside of work she enjoys spending time with family and friends and also loves baking and running.

Teodora Trasieva

Teodora is a Statistical Science Associate Director at AstraZeneca based in Gothenburg. She joined the company in 2015 after obtaining a MSc in Applied Statistics from Örebro University, Sweden and has worked predominantly on immunology late-stage clinical trials. She also did a secondment in the trial design methodology centre at AstraZeneca, where she consulted on trial design issues in oncology studies with focus on group sequential design and multiplicity. Teodora joined the PSI scientific committee in 2021.